US OptionsDetailed Quotes
PTN240816C2500
- 0.02
- 0.000.00%
15min DelayTrading Aug 12 10:06 ET
0.00High0.00Low
0.00Open0.02Pre Close0 Volume198 Open Interest2.50Strike Price0.00Turnover408.73%IV82.61%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.02Extrinsic Value100Contract SizeAmericanOptions Type0.0924Delta0.3064Gamma69.00Leverage Ratio-0.0116Theta0.0000Rho6.38Eff Leverage0.0002Vega
Palatin Technologies Stock Discussion
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
Palatin Technologies, Inc. (NYSE American: PTN), a pioneering biopharmaceutical company, has recently made a significant stride in the treatment of obesity by gaining FDA clearance for its Investigational New Drug (IND) application. This clearance allows Palatin to proceed with a Phase 2 clinical study e...
Palatin Announces FDA Clearance of Ind Application for the Co-Administration of Bremelanotide With Tirzepatide (GLP-1) for the Treatment of Obesity
NEWS
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity
NEWS
Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024
In a significant development for millions suffering from Dry Eye Disease (DED), Palatin Technologies, Inc. recently unveiled the results of their Phase 3 PL9643 MELODY-1 clinical trial at the prestigious American Society of Cataract and Refractive Surgery (ASCRS) conference in 2024. The findings mark a promising advancement...
$Palatin Technologies (PTN.US)$ this company is huge opportunity it has massive funding with 6B USD it’s go to the top 100% sure.
my advice is buy
the $Palatin Technologies (PTN.US)$ will go to the point because it has 6B USD funding
now buy this is moment
No comment yet